Shopping Cart
- Remove All
- Your shopping cart is currently empty
Claudin-18 Protein, Human, Recombinant (CLDN18.1) is expressed in HEK293 mammalian cells. The predicted molecular weight is 27.86 kDa and the accession number is P56856-1.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
20 μg | $838 | 7-10 days | |
100 μg | $1,670 | 7-10 days | |
500 μg | $5,310 | 7-10 days |
Biological Activity | Immobilized Human Claudin18.1-VLP (Full Length) Protein at 5 μg/mL (100 μL/well) can bind Anti-Human claudin18.1 Antibody, Rabbit IgG1, the EC50 is 0.8 ng/mL (QC tested). |
Description | Claudin-18 Protein, Human, Recombinant (CLDN18.1) is expressed in HEK293 mammalian cells. The predicted molecular weight is 27.86 kDa and the accession number is P56856-1. |
Species | Human |
Expression System | HEK293 Cells |
Tag | Tag Free |
Accession Number | P56856-1 |
Synonyms | SFTPJ,SFTA5,claudin 18 |
Construction | A DNA sequence encoding the human CLDN18 (P56856-1) (Met1-Val261) was expressed. Predicted N terminal: Met 1 |
Molecular Weight | 27.86 kDa (predicted) |
Endotoxin | < 1.0 EU/μg of the protein as determined by the LAL method. |
Formulation | Supplied as sterile 50 mM Hepes, 150 mM NaCl 10% Trehalose, pH 7.2. |
Stability & Storage | It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
Shipping | Shipping with blue ice. |
Research Background | Claudins family member Claudin18 (CLDN18) is a four-pass transmembrane protein with two extracellular loops and cytoplasmic N- and C-tails found in tight junctions. CLDN18 modulates paracellular permeability, polarity, and signaling. CLDN18 deficiency has been associated with atrophic gastritis, spasmolytic polypeptide-expressing metaplasia (SPEM), and asthma. Lung-specific CLDN18.1 modulates alveolar epithelial type II (AT2) cell proliferation and organ size. Restoration of CLDN18.1 expression in human lung cancer cells has been shown to suppress proliferation, inhibiting the IGF-1R/AKT axes. Not expressed in other healthy tissues, gastric mucosa-specific isoform CLDN18.2 expression manifests in primary gastric cancers. CLDN18.2 at the surface of epithelial tumor cells is a target in antibody and CAR-therapies currently in development. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.